In a regulatory filing, Intra-Cellular director Joel Marcus disclosed the sale of 10,000 common shares of the company on August 11 at a price of $59.22 per share.

Akumin provided a business update and announced the termination of employment of its CFO, William Larkin and the appointment of David Kretschmer as Interim CFO, effective August 12. The company has implemented a transformation program with initiatives focused on its operations, growth, and capital. These initiatives are intended to support the company's objectives with respect to patient access and experience, customer and partner engagement, financial sustainability, and employee well-being. The company is receiving support from a globally recognized transformation specialist to help implement the program. As a part of this transformation, the company announced: (a) the termination of employment of its CFO, William Larkin, and the appointment of David Kretschmer, an experienced transformation finance executive who successfully completed other business transformations in the healthcare industry, as Interim CFO, effective August 12; and (b) the sale of certain accounts receivables by subsidiaries of the company to a third-party buyer for a purchase price of approximately $30M.

Edoc Acquisition Corp., a special purpose acquisition company, announced the termination of its previously announced agreement and plan of merger with Calidi Biotherapeutics. Although Edoc and Calidi may continue to discuss the possibility of engaging in a business combination, there can be no assurance that those discussions will result in a transaction between Edoc and Calidi proceeding on the current terms of the Business Combination, if at all. As a result of the termination of the Merger Agreement, Edoc intends to promptly begin simultaneously evaluating other possible business combination targets.

Nelson Peltz's Trian Fund Management disclosed in an SEC filing its holdings as of June 30, 2022. The fund increased its stake in three holdings during the second quarter, including by size of previous position Ferguson (FERG), General Electric (GE), and Invesco (IVZ). Trian reduced its stake in two holdings, including by size of previous position Sysco (SYY) and Mondelez (MDLZ). The fund's top holdings as of June 30, in order of size, were Ferguson, Invesco, Janus Henderson (JHG), Sysco, and Wendy's (WEN).

Carnival Cruise Line announced protocol updates that meet public health goals but recognize the evolving nature of COVID-19. With these changes, the company said it is making it easier for more guests to sail with simplified vaccination and testing guidelines, including no testing for vaccinated guests on sailings less than 16 nights, and eliminating the exemption request process for unvaccinated guests, who will only need to show a negative test result at embarkation. All new guidelines are effective for cruises departing on Tuesday, Sept. 6, 2022 or later, and include: Vaccinated guests must continue to provide evidence of their vaccination status prior to embarkation. Pre-cruise testing is no longer required, except for cruises to Canada, Bermuda, Greece and Australia (per local guidelines), and on voyages 16 nights or longer. Unvaccinated guests are welcome to sail and are no longer required to apply for a vaccine exemption, except for cruises in Australia or on voyages 16 nights and longer. Unvaccinated guests or those who do not provide proof of vaccination must present the results of a negative PCR or antigen test taken within three days of embarkation. All policies are subject to local destination regulations. Voyages 16 nights and longer will continue to have vaccination and testing requirements that are specific to the itinerary.